Compound ID | 3193
Class: Beta-lactamase (cephalosporin) + beta-lactamase inhibitor
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against extended-spectrum β-lactamase producing Escherichia coli (harbouring bla-CTX-M-15); indicated for infections of the urinary tract and respiratory tract; targets cell wall synthesis |
| Description: | Drug combination; formulated for injection; cephalosporin-type beta-lactam |
| Institute where first reported: | Xiangbei Welman Pharmaceutical Co., Ltd |
| Year first mentioned: | 2007 |
| Highest developmental phase: | Phase 4 (NCT04066621) |
| Development status: | Active (as of 2024) |
| External links: | |
| Citation: | https://academic.oup.com/jac/article/60/1/187/729781?login=true |